I am a shareholder of Global Med Technologies. I have a modest position of just ten shares. Recently I received a document requiring my vote on weather to allow a firm to purchase Global Med. The proposed purchase price is $1.22 per share, well below what I believe the firm is worth. However, $1.22 is significantly higher than the current book value of the firm, just eight cents. Currently the firm has more debt than cash, and their profit margin is a meager 3.24%. Although I do not want this acquisition to occur, I believe it is the best option for the firm and its shareholders.
I would like to thank Michael Ruxin for his years of dedicated service as the CEO of Global Med Technologis. I look forward to investing in his next venture.